{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:25:54Z","timestamp":1789475154529,"version":"build-2803163510"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11154-022-09719-8","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T03:02:20Z","timestamp":1647399740000},"page":"659-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sex differences in carcinoid syndrome: A gap to be closed"],"prefix":"10.1007","volume":"23","author":[{"given":"Rosaria M.","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Grossrubatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Minotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Tarsitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Zamponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"MIsidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antongiulio","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"NIKE Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"issue":"4","key":"9719_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1515\/cclm-2012-0849","volume":"51","author":"G Baggio","year":"2013","unstructured":"Baggio G, Corsini A, Floreani A, Giannini S, Zagonel V. Gender medicine: a task for the third millennium. Clin Chem Lab Med. 2013;51(4):713\u201327.","journal-title":"Clin Chem Lab Med"},{"issue":"6\u20137","key":"9719_CR2","doi-asserted-by":"publisher","first-page":"A479","DOI":"10.1016\/j.autrev.2011.11.022","volume":"11","author":"S Oertelt-Prigione","year":"2012","unstructured":"Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun Rev. 2012;11(6\u20137):A479\u201385.","journal-title":"Autoimmun Rev"},{"key":"9719_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fgene.2012.00268","volume":"3","author":"MT Dorak","year":"2012","unstructured":"Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet. 2012;3:268.","journal-title":"Front Genet"},{"issue":"1","key":"9719_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000505500","volume":"36","author":"MT Mogl","year":"2020","unstructured":"Mogl MT, Dobrindt EM, Buscherm\u00f6hle J, Bures C, Pratschke J, Amthauer H, et al. Influence of gender on therapy and outcome of neuroendocrine tumors of gastroenteropancreatic origin: a single-center analysis. Visc Med. 2020;36(1):20\u20137.","journal-title":"Visc Med"},{"issue":"2","key":"9719_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12020-020-02331-3","volume":"69","author":"G Muscogiuri","year":"2020","unstructured":"Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, et al. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine. 2020;69(2):441\u201350.","journal-title":"Endocrine"},{"issue":"9","key":"9719_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tem.2020.02.010","volume":"31","author":"G Muscogiuri","year":"2020","unstructured":"Muscogiuri G, Barrea L, Feola T, Gallo M, Messina E, Venneri MA, et al. Pancreatic neuroendocrine neoplasms: Does sex matter? Trends Endocrinol Metab. 2020;31(9):631\u201341.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"9719_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11154-020-09547-8","volume":"21","author":"G Fanciulli","year":"2020","unstructured":"Fanciulli G, Ruggeri RM, Grossrubatscher E, Calzo FL, Wood TD, Faggiano A, et al. Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord. 2020;21(4):599\u2013612.","journal-title":"Rev Endocr Metab Disord"},{"key":"9719_CR8","unstructured":"Pandit S, Annamaraju P, Bhusal K. Carcinoid Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright \u00a9 2022, StatPearls Publishing LLC.; 2022."},{"issue":"5","key":"9719_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.amjsurg.2004.01.019","volume":"187","author":"S Toth-Fejel","year":"2004","unstructured":"Toth-Fejel S, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg. 2004;187(5):575\u20139.","journal-title":"Am J Surg"},{"issue":"4","key":"9719_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334.","journal-title":"Lancet Oncol"},{"issue":"3","key":"9719_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.surg.2018.09.008","volume":"165","author":"CW Kimbrough","year":"2019","unstructured":"Kimbrough CW, Beal EW, Dillhoff ME, Schmidt CR, Pawlik TM, Lopez-Aguiar AG, et al. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery. 2019;165(3):657\u201363.","journal-title":"Surgery"},{"issue":"40","key":"9719_CR12","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.3748\/wjg.v23.i40.7283","volume":"23","author":"B Cai","year":"2017","unstructured":"Cai B, Broder MS, Chang E, Yan T, Metz DC. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. World J Gastroenterol. 2017;23(40):7283\u201391.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"9719_CR13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1080\/10408398.2017.1390729","volume":"59","author":"M Gallo","year":"2019","unstructured":"Gallo M, Muscogiuri G, Pizza G, Ruggeri RM, Barrea L, Faggiano A, et al. The management of neuroendocrine tumours: a nutritional viewpoint. Crit Rev Food Sci Nutr. 2019;59(7):1046\u201357.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"2","key":"9719_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11154-018-9466-z","volume":"19","author":"B Altieri","year":"2018","unstructured":"Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A, et al. Nutrition and neuroendocrine tumors: an update of the literature. Rev Endocr Metab Disord. 2018;19(2):159\u201367.","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"9719_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/0024-3205(88)90543-7","volume":"43","author":"J Ortiz","year":"1988","unstructured":"Ortiz J, Artigas F, Gelp\u00ed E. Serotonergic status in human blood. Life Sci. 1988;43(12):983\u201390.","journal-title":"Life Sci"},{"key":"9719_CR16","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3389\/fnins.2019.01375","volume":"13","author":"B Chakraborti","year":"2019","unstructured":"Chakraborti B, Verma D, Guhathakurta S, Jaiswal P, Singh AS, Sinha S, et al. Gender-specific effect of 5-HT and 5-HIAA on threshold level of behavioral symptoms and sex-bias in prevalence of autism spectrum disorder. Front Neurosci. 2019;13:1375.","journal-title":"Front Neurosci"},{"issue":"9","key":"9719_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1365-2036.2009.04121.x","volume":"30","author":"LA Houghton","year":"2009","unstructured":"Houghton LA, Brown H, Atkinson W, Morris J, Fell C, Whorwell PJ, et al. 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status. Aliment Pharmacol Ther. 2009;30(9):919\u201329.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9719_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.lfs.2004.06.024","volume":"76","author":"N Pivac","year":"2004","unstructured":"Pivac N, M\u00fcck-Seler D, Mustapi\u0107 M, Nenadi\u0107-Sviglin K, Kozari\u0107-Kovaci\u0107 D. Platelet serotonin concentration in alcoholic subjects. Life Sci. 2004;76(5):521\u201331.","journal-title":"Life Sci"},{"issue":"1","key":"9719_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41531-021-00172-z","volume":"7","author":"A van Rumund","year":"2021","unstructured":"van Rumund A, Pavelka L, Esselink RAJ, Geurtz BPM, Wevers RA, Mollenhauer B, et al. Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. NPJ Parkinsons Dis. 2021;7(1):29.","journal-title":"NPJ Parkinsons Dis"},{"issue":"6","key":"9719_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cpr.2010.04.011","volume":"30","author":"T Hildebrandt","year":"2010","unstructured":"Hildebrandt T, Alfano L, Tricamo M, Pfaff DW. Conceptualizing the role of estrogens and serotonin in the development and maintenance of bulimia nervosa. Clin Psychol Rev. 2010;30(6):655\u201368.","journal-title":"Clin Psychol Rev"},{"key":"9719_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.biochi.2019.03.023","volume":"161","author":"AAH Thibeault","year":"2019","unstructured":"Thibeault AAH, Sanderson JT, Vaillancourt C. Serotonin-estrogen interactions: What can we learn from pregnancy? Biochimie. 2019;161:88\u2013108.","journal-title":"Biochimie"},{"key":"9719_CR22","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","volume":"9","author":"EB Thangam","year":"2018","unstructured":"Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018;9:1873.","journal-title":"Front Immunol"},{"key":"9719_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neuroscience.2015.06.049","volume":"303","author":"JN Li","year":"2015","unstructured":"Li JN, Li XL, He J, Wang JX, Zhao M, Liang XB, et al. Sex- and afferent-specific differences in histamine receptor expression in vagal afferents of rats: a potential mechanism for sexual dimorphism in prevalence and severity of asthma. Neuroscience. 2015;303:166\u201377.","journal-title":"Neuroscience"},{"key":"9719_CR24","doi-asserted-by":"crossref","unstructured":"Mackey E, Ayyadurai S, Pohl CS, D\u2019Costa S, Li Y, Moeser AJ. Sexual dimorphism in the mast cell transcriptome and the pathophysiological responses to immunological and psychological stress. Biol Sex Differ. 2016;7:60.","DOI":"10.1186\/s13293-016-0113-7"},{"issue":"3","key":"9719_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12016-017-8661-0","volume":"56","author":"E Ridolo","year":"2019","unstructured":"Ridolo E, Incorvaia C, Martignago I, Caminati M, Canonica GW, Senna G. Sex in respiratory and skin allergies. Clin Rev Allergy Immunol. 2019;56(3):322\u201332.","journal-title":"Clin Rev Allergy Immunol"},{"key":"9719_CR26","doi-asserted-by":"crossref","unstructured":"Comas-Bast\u00e9 O, S\u00e1nchez-P\u00e9rez S, Veciana-Nogu\u00e9s MT, Latorre-Moratalla M, Vidal-Carou MDC. Histamine intolerance: the current state of the art. Biomolecules. 2020;10(8).","DOI":"10.3390\/biom10081181"},{"issue":"16\u201317","key":"9719_CR27","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.clinbiochem.2007.07.019","volume":"40","author":"E Garc\u00eda-Mart\u00edn","year":"2007","unstructured":"Garc\u00eda-Mart\u00edn E, Ayuso P, Mart\u00ednez C, Ag\u00fandez JA. Improved analytical sensitivity reveals the occurrence of gender-related variability in diamine oxidase enzyme activity in healthy individuals. Clin Biochem. 2007;40(16\u201317):1339\u201341.","journal-title":"Clin Biochem"},{"issue":"1","key":"9719_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13105-017-0571-3","volume":"74","author":"J Izquierdo-Casas","year":"2018","unstructured":"Izquierdo-Casas J, Comas-Bast\u00e9 O, Latorre-Moratalla ML, Lorente-Gasc\u00f3n M, Duelo A, Vidal-Carou MC, et al. Low serum diamine oxidase (DAO) activity levels in patients with migraine. J Physiol Biochem. 2018;74(1):93\u20139.","journal-title":"J Physiol Biochem"},{"issue":"6","key":"9719_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.vph.2004.02.002","volume":"40","author":"J Klocker","year":"2004","unstructured":"Klocker J, Perkmann R, Klein-Weigel P, M\u00f6rsdorf G, Drasche A, Klingler A, et al. Continuous administration of heparin in patients with deep vein thrombosis can increase plasma levels of diamine oxidase. Vascul Pharmacol. 2004;40(6):293\u2013300.","journal-title":"Vascul Pharmacol"},{"issue":"1\u20132","key":"9719_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.clinbiochem.2012.10.013","volume":"46","author":"Y Hamada","year":"2013","unstructured":"Hamada Y, Shinohara Y, Yano M, Yamamoto M, Yoshio M, Satake K, et al. Effect of the menstrual cycle on serum diamine oxidase levels in healthy women. Clin Biochem. 2013;46(1\u20132):99\u2013102.","journal-title":"Clin Biochem"},{"issue":"4","key":"9719_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jclinane.2010.12.009","volume":"23","author":"K Mancuso","year":"2011","unstructured":"Mancuso K, Kaye AD, Boudreaux JP, Fox CJ, Lang P, Kalarickal PL, et al. Carcinoid syndrome and perioperative anesthetic considerations. J Clin Anesth. 2011;23(4):329\u201341.","journal-title":"J Clin Anesth"},{"issue":"4","key":"9719_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/1354750X.2013.787544","volume":"18","author":"E Kashuba","year":"2013","unstructured":"Kashuba E, Bailey J, Allsup D, Cawkwell L. The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers. 2013;18(4):279\u201396.","journal-title":"Biomarkers"},{"issue":"3","key":"9719_CR33","doi-asserted-by":"publisher","first-page":"H845","DOI":"10.1152\/ajpheart.00160.2002","volume":"283","author":"A Sato","year":"2002","unstructured":"Sato A, Miura H, Liu Y, Somberg LB, Otterson MF, Demeure MJ, et al. Effect of gender on endothelium-dependent dilation to bradykinin in human adipose microvessels. Am J Physiol Heart Circ Physiol. 2002;283(3):H845\u201352.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"Pt 2","key":"9719_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1113\/jphysiol.2003.044107","volume":"551","author":"GL Hoetzer","year":"2003","unstructured":"Hoetzer GL, Stauffer BL, Irmiger HM, Ng M, Smith DT, DeSouza CA. Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women. J Physiol. 2003;551(Pt 2):721\u20138.","journal-title":"J Physiol"},{"issue":"12","key":"9719_CR35","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1111\/j.1572-0241.2004.40507.x","volume":"99","author":"IM Modlin","year":"2004","unstructured":"Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol. 2004;99(12):2466\u201378.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"9719_CR36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1530\/ERC-17-0282","volume":"25","author":"A Bla\u017eevi\u0107","year":"2018","unstructured":"Bla\u017eevi\u0107 A, Zandee WT, Franssen GJH, Hofland J, van Velthuysen MF, Hofland LJ, et al. Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer. 2018;25(3):245\u201354.","journal-title":"Endocr Relat Cancer"},{"key":"9719_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000382053","volume":"44","author":"G Boutzios","year":"2015","unstructured":"Boutzios G, Kaltsas G. Clinical syndromes related to gastrointestinal neuroendocrine neoplasms. Front Horm Res. 2015;44:40\u201357.","journal-title":"Front Horm Res"},{"key":"9719_CR38","unstructured":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17\u201330."},{"issue":"2","key":"9719_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000492178","volume":"3","author":"H Imaeda","year":"2018","unstructured":"Imaeda H, Hibi T. The burden of diverticular disease and its complications: West versus east. Inflamm Intest Dis. 2018;3(2):61\u20138.","journal-title":"Inflamm Intest Dis"},{"key":"9719_CR40","doi-asserted-by":"crossref","unstructured":"Lapides RA, Savaiano DA. Gender, age, race and lactose intolerance: is there evidence to support a differential symptom response? A scoping review. Nutrients. 2018;10(12).","DOI":"10.3390\/nu10121956"},{"issue":"1","key":"9719_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ajg.2010.371","volume":"106","author":"CK Porter","year":"2011","unstructured":"Porter CK, Gormley R, Tribble DR, Cash BD, Riddle MS. The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol. 2011;106(1):130\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"9719_CR42","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","volume":"16","author":"P Singh","year":"2018","unstructured":"Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global prevalence of celiac disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823-36.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"9719_CR43","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1136\/gut.2007.119446","volume":"56","author":"R Spiller","year":"2007","unstructured":"Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: Mechanisms and practical management. Gut. 2007;56(12):1770\u201398.","journal-title":"Gut"},{"issue":"1","key":"9719_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/gut.2011.238386","volume":"61","author":"CC Tam","year":"2012","unstructured":"Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter PR, et al. Longitudinal study of infectious intestinal disease in the UK (IID2 study): Incidence in the community and presenting to general practice. Gut. 2012;61(1):69\u201377.","journal-title":"Gut"},{"issue":"4","key":"9719_CR45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40519-017-0432-7","volume":"22","author":"S Valente","year":"2017","unstructured":"Valente S, Di Girolamo G, Forlani M, Biondini A, Scudellari P, De Ronchi D, et al. Sex-specific issues in eating disorders: a clinical and psychopathological investigation. Eat Weight Disord. 2017;22(4):707\u201315.","journal-title":"Eat Weight Disord"},{"issue":"2","key":"9719_CR46","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s11605-007-0177-0","volume":"12","author":"AA Ghaferi","year":"2008","unstructured":"Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPomas: Subject review and one institutional experience. J Gastrointest Surg. 2008;12(2):382\u201393.","journal-title":"J Gastrointest Surg"},{"issue":"9","key":"9719_CR47","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2017-00992","volume":"102","author":"O Hamidi","year":"2017","unstructured":"Hamidi O, Young WF Jr, I\u00f1iguez-Ariza NM, Kittah NE, Gruber L, Bancos C, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102(9):3296\u2013305.","journal-title":"J Clin Endocrinol Metab"},{"key":"9719_CR48","doi-asserted-by":"crossref","unstructured":"Neumann HPH, Tsoy U, Bancos I, Amodru V, Walz MK, Tirosh A, et al. Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy. JAMA Netw Open. 2019;2(8):e198898.","DOI":"10.1001\/jamanetworkopen.2019.8898"},{"issue":"5","key":"9719_CR49","doi-asserted-by":"publisher","first-page":"R219","DOI":"10.1530\/EJE-17-0295","volume":"177","author":"I Huguet","year":"2017","unstructured":"Huguet I, Grossman A. Management of endocrine disease: Flushing: current concepts. Eur J Endocrinol. 2017;177(5):R219\u201329.","journal-title":"Eur J Endocrinol"},{"key":"9719_CR50","doi-asserted-by":"crossref","unstructured":"Valassi E, Santos A, Yaneva M, T\u00f3th M, Strasburger CJ, Chanson P, et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165(3):383\u201392.","DOI":"10.1530\/EJE-11-0272"},{"issue":"11","key":"9719_CR51","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nrendo.2016.110","volume":"12","author":"CM Kitahara","year":"2016","unstructured":"Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12(11):646\u201353.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"9719_CR52","first-page":"133","volume":"18","author":"J Soga","year":"1999","unstructured":"Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. 1999;18(2):133\u201341.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"9719_CR53","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.ijporl.2012.08.008","volume":"76","author":"Z Huankang","year":"2012","unstructured":"Huankang Z, Kuanlin X, Xiaolin H, Witt D. Comparison between tracheal foreign body and bronchial foreign body: a review of 1,007 cases. Int J Pediatr Otorhinolaryngol. 2012;76(12):1719\u201325.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"1","key":"9719_CR54","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaci.2016.04.029","volume":"139","author":"S Lee","year":"2017","unstructured":"Lee S, Hess EP, Lohse C, Gilani W, Chamberlain AM, Campbell RL. Trends, characteristics, and incidence of anaphylaxis in 2001\u20132010: a population-based study. J Allergy Clin Immunol. 2017;139(1):182-8.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"9719_CR55","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood. 2009;113(23):5727\u201336.","journal-title":"Blood"},{"key":"9719_CR56","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.3389\/fimmu.2018.02997","volume":"9","author":"R Shah","year":"2018","unstructured":"Shah R, Newcomb DC. Sex bias in asthma prevalence and pathogenesis. Front Immunol. 2018;9:2997.","journal-title":"Front Immunol"},{"issue":"3","key":"9719_CR57","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461\u20136.","journal-title":"Pancreas"},{"key":"9719_CR58","doi-asserted-by":"crossref","unstructured":"Fr\u00f6jd C, Larsson G, Lampic C, von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;5:18.","DOI":"10.1186\/1477-7525-5-18"},{"issue":"4","key":"9719_CR59","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1097\/NCC.0000000000000614","volume":"42","author":"T Haugland","year":"2019","unstructured":"Haugland T, DeVon HA. Symptoms, psychosocial factors, and health-related quality of life in patients with neuroendocrine tumors: an integrative review. Cancer Nurs. 2019;42(4):E36-e46.","journal-title":"Cancer Nurs"},{"issue":"9","key":"9719_CR60","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1007\/s00520-016-3189-z","volume":"24","author":"TP Pearman","year":"2016","unstructured":"Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016;24(9):3695\u2013703.","journal-title":"Support Care Cancer"},{"issue":"3","key":"9719_CR61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10555-015-9573-1","volume":"34","author":"P Jim\u00e9nez-Fonseca","year":"2015","unstructured":"Jim\u00e9nez-Fonseca P, Carmona-Bayonas A, Mart\u00edn-P\u00e9rez E, Crespo G, Serrano R, Llanos M, et al. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2015;34(3):381\u2013400.","journal-title":"Cancer Metastasis Rev"},{"key":"9719_CR62","doi-asserted-by":"crossref","unstructured":"Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med. 1995;237(3):269\u201375.","DOI":"10.1111\/j.1365-2796.1995.tb01175.x"},{"issue":"1","key":"9719_CR63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12885-019-5459-x","volume":"19","author":"DM Halperin","year":"2019","unstructured":"Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, et al. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer. 2019;19(1):274.","journal-title":"BMC Cancer"},{"issue":"1","key":"9719_CR64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1756283X16674660","volume":"10","author":"DL Chan","year":"2017","unstructured":"Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol. 2017;10(1):132\u201341.","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"9719_CR65","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12955-016-0527-2","volume":"14","author":"C Martini","year":"2016","unstructured":"Martini C, Gamper EM, Wintner L, Nilica B, Sperner-Unterweger B, Holzner B, et al. Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes. 2016;14(1):127.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"9719_CR66","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1210\/clinem\/dgaa760","volume":"106","author":"C Scandurra","year":"2021","unstructured":"Scandurra C, Modica R, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, et al. Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience. J Clin Endocrinol Metab. 2021;106(1):e316\u201327.","journal-title":"J Clin Endocrinol Metab"},{"issue":"30","key":"9719_CR67","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1200\/JCO.2012.41.7915","volume":"30","author":"SL Bober","year":"2012","unstructured":"Bober SL, Varela VS. Sexuality in adult cancer survivors: Challenges and intervention. J Clin Oncol. 2012;30(30):3712\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9719_CR68","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1055\/s-0028-1093567","volume":"9","author":"JM Feldman","year":"1977","unstructured":"Feldman JM, Plonk JW. Pituitary-gonadal function in the carcinoid syndrome: Effect of parachlorophynylalanine therapy. Horm Metab Res. 1977;9(2):156\u201360.","journal-title":"Horm Metab Res"},{"issue":"6","key":"9719_CR69","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1743-6109.2009.01309.x","volume":"6","author":"JG Pfaus","year":"2009","unstructured":"Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6(6):1506\u201333.","journal-title":"J Sex Med"},{"issue":"1\u20132","key":"9719_CR70","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0006-8993(00)02076-X","volume":"862","author":"A Kato","year":"2000","unstructured":"Kato A, Sakuma Y. Neuronal activity in female rat preoptic area associated with sexually motivated behavior. Brain Res. 2000;862(1\u20132):90\u2013102.","journal-title":"Brain Res"},{"issue":"2","key":"9719_CR71","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.physbeh.2004.08.018","volume":"83","author":"EM Hull","year":"2004","unstructured":"Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: Influences on male sexual behavior. Physiol Behav. 2004;83(2):291\u2013307.","journal-title":"Physiol Behav"},{"issue":"4","key":"9719_CR72","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/S0306-4522(99)00082-2","volume":"92","author":"M Bancila","year":"1999","unstructured":"Bancila M, Verg\u00e9 D, Rampin O, Backstrom JR, Sanders-Bush E, McKenna KE, et al. 5-Hydroxytryptamine2C receptors on spinal neurons controlling penile erection in the rat. Neuroscience. 1999;92(4):1523\u201337.","journal-title":"Neuroscience"},{"key":"9719_CR73","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pbb.2013.11.017","volume":"121","author":"EM Snoeren","year":"2014","unstructured":"Snoeren EM, Veening JG, Olivier B, Oosting RS. Serotonin 1A receptors and sexual behavior in female rats: a review. Pharmacol Biochem Behav. 2014;121:43\u201352.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"9719_CR74","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","volume":"195","author":"J Hannon","year":"2008","unstructured":"Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res. 2008;195(1):198\u2013213.","journal-title":"Behav Brain Res"},{"issue":"2","key":"9719_CR75","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172\u201385.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"9719_CR76","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","volume":"46","author":"JR Strosberg","year":"2017","unstructured":"Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46(6):707\u201314.","journal-title":"Pancreas"},{"issue":"2","key":"9719_CR77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1758834016675803","volume":"9","author":"RP Riechelmann","year":"2017","unstructured":"Riechelmann RP, Pereira AA, Rego JF, Costa FP. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017;9(2):127\u201337.","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"9719_CR78","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/MPA.0b013e31821f66b4","volume":"40","author":"L Anthony","year":"2011","unstructured":"Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas. 2011;40(7):987\u201394.","journal-title":"Pancreas"},{"issue":"10","key":"9719_CR79","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.22272","volume":"107","author":"E Bajetta","year":"2006","unstructured":"Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer. 2006;107(10):2474\u201381.","journal-title":"Cancer"},{"key":"9719_CR80","doi-asserted-by":"crossref","unstructured":"di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77(2):402\u20138.","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4"},{"issue":"11","key":"9719_CR81","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","volume":"95","author":"M Ducreux","year":"2000","unstructured":"Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95(11):3276\u201381.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"9719_CR82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1634\/theoncologist.2017-0284","volume":"23","author":"GA Fisher Jr","year":"2018","unstructured":"Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, et al. Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot\/autogel: Results from a randomized, placebo-controlled, double-blind and 32-week open-label study. Oncologist. 2018;23(1):16\u201324.","journal-title":"Oncologist"},{"issue":"3","key":"9719_CR83","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1046\/j.1365-2036.2003.01420.x","volume":"17","author":"J Garland","year":"2003","unstructured":"Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther. 2003;17(3):437\u201344.","journal-title":"Aliment Pharmacol Ther"},{"key":"9719_CR84","doi-asserted-by":"crossref","unstructured":"Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32(2):225\u20139.","DOI":"10.3109\/02841869309083916"},{"issue":"2","key":"9719_CR85","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","volume":"34","author":"MS Khan","year":"2011","unstructured":"Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34(2):235\u201342.","journal-title":"Aliment Pharmacol Ther"},{"key":"9719_CR86","doi-asserted-by":"crossref","unstructured":"Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663\u20136.","DOI":"10.1056\/NEJM198609113151102"},{"key":"9719_CR87","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/1471-2407-13-427","volume":"13","author":"M Mart\u00edn-Richard","year":"2013","unstructured":"Mart\u00edn-Richard M, Massut\u00ed B, Pineda E, Alonso V, Marmol M, Castellano D, et al. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 2013;13:427.","journal-title":"BMC Cancer"},{"issue":"2","key":"9719_CR88","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9719_CR89","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000082875","volume":"80","author":"P Ruszniewski","year":"2004","unstructured":"Ruszniewski P, Ish-Shalom S, Wymenga M, O\u2019Toole D, Arnold R, Tomassetti P, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80(4):244\u201351.","journal-title":"Neuroendocrinology"},{"issue":"5","key":"9719_CR90","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","volume":"48","author":"P Ruszniewski","year":"2016","unstructured":"Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, et al. Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: an international observational study. Dig Liver Dis. 2016;48(5):552\u20138.","journal-title":"Dig Liver Dis"},{"issue":"9","key":"9719_CR91","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4158\/EP151172.OR","volume":"22","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068\u201380.","journal-title":"Endocr Pract"},{"issue":"4","key":"9719_CR92","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","volume":"17","author":"AN Wymenga","year":"1999","unstructured":"Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17(4):1111.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9719_CR93","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/02841869109092409","volume":"30","author":"K Oberg","year":"1991","unstructured":"Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol. 1991;30(4):503\u20137.","journal-title":"Acta Oncol"},{"issue":"3","key":"9719_CR94","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4158\/EP172000.OR","volume":"24","author":"GA Fisher Jr","year":"2018","unstructured":"Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, et al. Lanreotide therapy in carcinoid syndrome: prospective analysis of patient-reported symptoms in patients responsive to prior octreotide therapy and patients na\u00efve to somatostatin analogue therapy in the elect phase 3 study. Endocr Pract. 2018;24(3):243\u201355.","journal-title":"Endocr Pract"},{"issue":"1","key":"9719_CR95","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2214\/ajr.147.1.149","volume":"147","author":"CH Carrasco","year":"1986","unstructured":"Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986;147(1):149\u201354.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"9719_CR96","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00330-002-1558-0","volume":"13","author":"A Roche","year":"2003","unstructured":"Roche A, Girish BV, de Ba\u00e8re T, Baudin E, Boige V, Elias D, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13(1):136\u201340.","journal-title":"Eur Radiol"},{"issue":"1","key":"9719_CR97","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, H\u00f6rsch D, Caplin ME, Anthony LB, Bergsland E, \u00d6berg K, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14\u201323.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9719_CR98","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1530\/ERC-17-0455","volume":"25","author":"M Pavel","year":"2018","unstructured":"Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, et al. Telotristat ethyl in carcinoid syndrome: Safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309\u201322.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"9719_CR99","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.clinthera.2018.10.008","volume":"40","author":"D Cella","year":"2018","unstructured":"Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, et al. Relationship between symptoms and health-related quality-of-life benefits in patients with carcinoid syndrome: Post hoc analyses from TELESTAR. Clin Ther. 2018;40(12):2006-20.e2.","journal-title":"Clin Ther"},{"issue":"6","key":"9719_CR100","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.clinthera.2018.04.006","volume":"40","author":"MO Weickert","year":"2018","unstructured":"Weickert MO, Kaltsas G, H\u00f6rsch D, Lapuerta P, Pavel M, Valle JW, et al. Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome. Clin Ther. 2018;40(6):952-62.e2.","journal-title":"Clin Ther"},{"key":"9719_CR101","doi-asserted-by":"crossref","unstructured":"H\u00f6rsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, et al. Long-term treatment with telotristat ethyl in patients with carcinoid syndrome symptoms: Results from the TELEPATH study. Neuroendocrinology. 2021.","DOI":"10.1159\/000516958"},{"issue":"7","key":"9719_CR102","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/bjs.1800810725","volume":"81","author":"EW McDermott","year":"1994","unstructured":"McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg. 1994;81(7):1007\u20139.","journal-title":"Br J Surg"},{"issue":"8","key":"9719_CR103","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/sj.bjc.6603699","volume":"96","author":"V Formica","year":"2007","unstructured":"Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, et al. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007;96(8):1178\u201382.","journal-title":"Br J Cancer"},{"issue":"10","key":"9719_CR104","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/1097-0142(19871115)60:10<2476::AID-CNCR2820601022>3.0.CO;2-R","volume":"60","author":"RS Greenberg","year":"1987","unstructured":"Greenberg RS, Baumgarten DA, Clark WS, Isacson P, McKeen K. Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer. 1987;60(10):2476\u201383.","journal-title":"Cancer"},{"issue":"7","key":"9719_CR105","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1023\/A:1008215730767","volume":"8","author":"ET Janson","year":"1997","unstructured":"Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685\u201390.","journal-title":"Ann Oncol"},{"issue":"18","key":"9719_CR106","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9719_CR107","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589\u201397.","journal-title":"Cancer"},{"issue":"6","key":"9719_CR108","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/ijc.31137","volume":"142","author":"R Boyar Cetinkaya","year":"2018","unstructured":"Boyar Cetinkaya R, Aagnes B, Myklebust T, Thiis-Evensen E. Survival in neuroendocrine neoplasms; a report from a large Norwegian population-based study. Int J Cancer. 2018;142(6):1139\u201347.","journal-title":"Int J Cancer"},{"issue":"1\u20132","key":"9719_CR109","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3121\/cmr.2017.1379a","volume":"16","author":"V Rastogi","year":"2018","unstructured":"Rastogi V, Singh D, Mazza JJ, Parajuli D, Yale SH. Flushing disorders associated with gastrointestinal symptoms: Part 1, neuroendocrine tumors, mast cell disorders and hyperbasophila. Clin Med Res. 2018;16(1\u20132):16\u201328.","journal-title":"Clin Med Res"},{"issue":"4","key":"9719_CR110","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934\u201359.","journal-title":"Cancer"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09719-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-022-09719-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09719-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T06:28:20Z","timestamp":1653978500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-022-09719-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["9719"],"URL":"https:\/\/doi.org\/10.1007\/s11154-022-09719-8","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"4 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}